Amarin Corp. AMRN, +4.67% received U.S. approval to market its drug Vascepa to reduce the risk of cardiovascular events in people with high triglyceride levels, according to the Food and Drug Administration late Friday. U.S.-traded shares were halted at $24.12 at 10:06 a.m. Eastern, hours before the announcement; when they resumed trading at 5:30 p.m., they gained more than 2% in after-hours action. "Vascepa is the first FDA approved drug to reduce cardiovascular risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy," the agency said in a statement. Vascepa was originally approved in 2012 to treat patients with severely high triglyceride levels. ADRs of Dublin-based Amarin are up 77% year-to-date, compared with a 26% rise in the S&P 500 index SPX, +1.59%